MicroRNA - 05/04/18

Abstract |
MicroRNAs (miRNAs) are small endogenous RNAs that regulate gene-expression posttranscriptionally. MiRNA research in allergy is expanding because miRNAs are crucial regulators of gene expression and promising candidates for biomarker development. MiRNA mimics and miRNA inhibitors currently in preclinical development have shown promise as novel therapeutic agents. Multiple technological platforms have been developed for miRNA isolation, miRNA quantitation, miRNA profiling, miRNA target detection, and modulating miRNA levels in vitro and in vivo. Here we will review the major technological platforms with consideration given for the advantages and disadvantages of each platform.
Le texte complet de cet article est disponible en PDF.Key words : Allergy, antagomiRs, antimiRs, CRISPR, CRISPR/Cas9, gene silencing, in situ hybridization, microarray, microRNA, microRNA methods, miRNA, miRNA expression, miRNA inhibitors, miRNA isolation, miRNA mimics, miRNA profiling, miRNA quantitation, miRNA targets, qPCR, stem-loop
Abbreviations used : Cas9, CRISPR, miRNA, qPCR, UTR
Plan
| Disclosure of potential conflict of interest: M. E. Rothenberg is a consultant for NKT Therapeutics, Pulm One, Spoon Guru, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare and Novartis; has an equity interest in the first 3 listed and Immune Pharmaceuticals, and royalties from reslizumab (Teva Pharmaceuticals); and is an inventor of patents, owned by Cincinnati Children's. T. X. Lu's institution received a grant from the National Institutes of Health for this work. |
Vol 141 - N° 4
P. 1202-1207 - avril 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
